皮肤性病门诊就诊患者支原体感染状况及耐药性分析

目的:探讨皮肤性病门诊就诊患者支原体感染状况及耐药性情况,为临床治疗提供依据。方法:通过分析2015年1月至2015年12月医院皮肤性病门诊收治的1546例性病患者的临床资料,采集患者生殖道分泌物标本并进行支原体培养,分析患者感染支原体类型及耐药性情况。结果:1546例性病患者中共有664例患者感染支原体,感染率占42.95%,其中感染解脲支原体(Uu)472例占比71.08%,感染人型支原体(Mh)患者有66例占比9.94%,混合感染患者126例占比18.98%;Uu对交沙霉素、原始霉素、四环素、强力霉素临床耐药率相对较低在5.00%以内,对左氧氟沙星和环丙沙星耐药率相对较高在40.00%以上;Mh对四环素、强力霉素、美满霉素、交沙霉素和原始霉素耐药率较低在10.00%之内,对阿奇霉素、克拉霉素和环丙沙星耐药率在50.00%以上;Uu+Mh混合感染患者临床耐药率显示其对红霉素、左氧氟沙星、阿奇霉素、环丙沙星和克拉霉素耐药率在70.00%以上,对强力霉素和原始霉素耐药率在10.00%之内。结论:对性病患者支原体感染类型及耐药性进行检测分析对生殖道感染患者的治疗有较大的临床价值。

Status and drug resistance of mycoplasma infection in dermatology clinic

Objectives:To investigate the status and drug resistance of mycoplasma infection in dermatology clinic,so as to provide basis for its clinical treatment.Methods:The clinical data of 1546 patients with sexually transmitted diseases from January 2015 to December 2015 was analyzed by collecting specimens of genital secretions and mycoplasma culture.Mycoplasma infection type and antibiotic resistance were analyzed.Results:Among the 1546 patients with sexually transmitted diseases,there were 664 patients infected with mycoplasma,accounting for 42.95％,of which there were 472 patients with UU infection,accounting for 71.08％,66 patients with mycoplasma hominis infection,accounting for 9.94％,and 126 patients with mixed infection,accounting for 18.98％;resistance rate of Uu to josamycin,pristinamycin,tetracycline and doxycycline was relatively low (less than 5.00％),and resistance rate to levofloxacin and ciprofloxacin was relatively high (more than 40.00％).The resistance rate of Mh to tetracycline,doxycycline,minocycline,josamycin and original neomycin was 10.00％,and resistance rate to azithromycin,clarithromycin and ciprofloxacin was 50.00％.The resistance rate of Uu + Mh to erythromycin,levofloxacin,azithromycin,ciprofloxacin and clarithromycin was more than 70.00％ and resistance rate to original doxycycline and neomycin was less than 10.00％.Conclusion:Analysis on type of STD patient mycoplasma infection and drug resistance has a good clinical value for the treatment of patients with genital tract infections.